Research graph
References from Risk factors for critical COVID-19 illness during Delta- and Omicron-predominant period in Korea; using K-COV-N cohort in the National health insurance service. Local targets link to admitted publications; unresolved targets remain external evidence.
Unresolved reference
External reference
The SARS-CoV-2 outbreak: what we know
10.1016/j.ijid.2020.03.004 · 2020 · External reference
Disease burden and clinical severity of the first pandemic wave of COVID-19 in Wuhan, China
10.1038/s41467-020-19238-2 · 2020 · External reference
SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness
10.1016/s0140-6736(21)01358-1 · 2021 · External reference
Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B. 1.617. 2) compared with alpha (B. 1.1. 7) variants of concern: a cohort study
10.1016/s1473-3099(21)00475-8 · 2022 · External reference
Epidemiology of Infections with SARS-CoV-2 Omicron BA.2 Variant, Hong Kong, January–March 2022
10.3201/eid2809.220613 · 2022 · External reference
Association between vaccination and acute myocardial infarction and ischemic stroke after COVID-19 infection
10.1001/jama.2022.12992 · 2022 · External reference
Risk factors for Covid-19 severity and fatality: a structured literature review
10.1007/s15010-020-01509-1 · 2021 · External reference
Unresolved reference
2021 · External reference
Unresolved reference
External reference
Risk factors for severe COVID-19 outcomes among persons aged≥ 18 years who completed a primary COVID-19 vaccination series—465 health care facilities, United States, December 2020–October 2021
10.15585/mmwr.mm7101a4 · 2022 · External reference
Risk of clinical severity by age and race/ethnicity among adults hospitalized for COVID-19—United States, March–September 2020
10.1093/ofid/ofaa638 · 2021 · External reference
Protective effect of COVID-19 vaccine among health care workers during the second wave of the pandemic in India
10.1016/j.mayocp.2021.06.003 · 2021 · External reference
Comparison of two highly-effective mRNA vaccines for COVID-19 during periods of Alpha and Delta variant prevalence
2021 · External reference
Effect of underlying comorbidities on the infection and severity of COVID-19 in Korea: a nationwide case-control study
2020 · External reference
Clinical characteristics and risk factors for mortality in critical coronavirus disease 2019 patients 50 years of age or younger during the delta wave: comparison with patients> 50 years in Korea
2022 · External reference
Mortality rate of infection with COVID-19 in Korea from the perspective of underlying disease
10.1017/dmp.2020.60 · 2020 · External reference
Autoimmune inflammatory rheumatic diseases and COVID-19 outcomes in South Korea: a nationwide cohort study
10.1016/s2665-9913(21)00151-x · 2021 · External reference
Non-alcoholic fatty liver disease and COVID-19 susceptibility and outcomes: a Korean nationwide cohort
2021 · External reference
Effect of Covid-19 vaccination on transmission of alpha and delta variants
10.1056/nejmoa2116597 · 2022 · External reference
Symptom prevalence, duration, and risk of hospital admission in individuals infected with SARS-CoV-2 during periods of omicron and delta variant dominance: a prospective observational study from the ZOE COVID Study
10.1016/s0140-6736(22)00327-0 · 2022 · External reference
Unequal burdens of COVID-19 infection: a nationwide cohort study of COVID-19-related health inequalities in Korea
2023 · External reference
Vaccine effectiveness against severe disease and death for patients with COVID-19 during the delta-dominant and omicron-emerging periods: a K-COVE study
2023 · External reference
Associations of symptom combinations with in-hospital mortality of coronavirus disease-2019 patients using South Korean National data
10.1371/journal.pone.0273654 · 2022 · External reference
Clinical Characteristics and Risk Factors for Mortality in Critical COVID-19 Patients Aged 50 Years or Younger During Omicron Wave in Korea: Comparison With Patients Older Than 50 Years of Age.
2023 · External reference
Variable effects of underlying diseases on the prognosis of patients with COVID-19
10.1371/journal.pone.0254258 · 2021 · External reference
Severe COVID-19 outcomes after full vaccination of primary schedule and initial boosters: pooled analysis of national prospective cohort studies of 30 million individuals in England, Northern Ireland, Scotland, and Wales
10.1016/s0140-6736(22)01656-7 · 2022 · External reference
Comparative analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron (B. 1.1. 529) and delta (B. 1.617. 2) variants in England: a cohort study
10.1016/s0140-6736(22)00462-7 · 2022 · External reference
Risk factors for COVID-19 hospitalization or death during the first Omicron surge in adults: A large population-based case-control study
2022 · External reference
Risk of severe clinical outcomes among persons with SARS-CoV-2 infection with differing levels of vaccination during widespread Omicron (B. 1.1. 529) and Delta (B. 1.617. 2) variant circulation in Northern California: A retrospective cohort study
2022 · External reference
Risk of hospitalisation associated with infection with SARS-CoV-2 omicron variant versus delta variant in Denmark: an observational cohort study
10.1016/s1473-3099(22)00154-2 · 2022 · External reference
Both underweight and obesity are associated with an increased risk of coronavirus disease 2019 (COVID-19) severity
2021 · External reference
Unresolved reference
2000 · External reference
Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases
10.1016/0895-4356(92)90133-8 · 1992 · External reference
COVID-19 variants in critically ill patients: A comparison of the Delta and Omicron variant profiles.
10.3390/idr14030052 · 2022 · External reference
Clinical characteristics of the severe acute respiratory syndrome coronavirus 2 omicron variant compared with the delta variant: A retrospective case-control study of 318 outpatients from a single sight institute in Japan
10.7717/peerj.13762 · 2022 · External reference
COVID‐19: Omicron–the latest, the least virulent, but probably not the last variant of concern of SARS‐CoV‐2
10.1111/1751-7915.14064 · 2022 · External reference
Is the Omicron variant truly less virulent in solid organ transplant recipients?
10.1111/tid.13923 · 2022 · External reference
COVID-19 in solid organ transplant recipients: a systematic review and meta-analysis of current literature
10.1016/j.trre.2020.100588 · 2021 · External reference
COVID-19 Hospitalization in Solid Organ Transplant Recipients on Immunosuppressive Therapy
10.1001/jamanetworkopen.2023.42006 · 2023 · External reference
Transplant-related immunosuppression: a review of immunosuppression and pulmonary infections
10.1513/pats.200507-073js · 2005 · External reference
General approach to the clinical care of solid organ transplant recipients with COVID-19 infection: management for transplant recipients
10.1007/s40472-020-00305-y · 2020 · External reference
Outcome of hospitalization for COVID-19 in patients with interstitial lung disease. An international multicenter study
10.1164/rccm.202007-2794oc · 2020 · External reference
Interstitial lung disease increases susceptibility to and severity of COVID-19
2021 · External reference
Risk factors for mortality after COVID-19 in patients with preexisting interstitial lung disease
10.1164/rccm.202007-2638le · 2021 · External reference
Increased odds of death for patients with interstitial lung disease and COVID-19: a case–control study
10.1164/rccm.202006-2441le · 2020 · External reference
Clinical characteristics of COVID-19 and active tuberculosis co-infection in an Italian reference hospital
10.1183/13993003.01708-2020 · 2020 · External reference
Impact of coronavirus disease-2019 on chronic respiratory disease in South Korea: an NHIS COVID-19 database cohort study
2021 · External reference
Implications of COVID-19 in high burden countries for HIV/TB: A systematic review of evidence
10.1186/s12879-020-05450-4 · 2020 · External reference
An updated meta‐analysis on the association between tuberculosis and COVID‐19 severity and mortality
10.1002/jmv.27119 · 2021 · External reference
Association between tuberculosis and COVID‐19 severity and mortality: a rapid systematic review and meta‐analysis
10.1002/jmv.26311 · 2021 · External reference
Unresolved reference
External reference
Clinical characteristics of COVID-19 in patients with tuberculosis and factors associated with the disease severity
10.1016/j.ijid.2022.04.041 · 2022 · External reference
COVID-19 pneumonia and the subsequent risk of getting active pulmonary tuberculosis: a population-based dynamic cohort study using national insurance claims databases
2023 · External reference
Obesity is a risk factor for developing critical condition in COVID‐19 patients: a systematic review and meta‐analysis
10.1111/obr.13095 · 2020 · External reference
The impact of obesity on severe disease and mortality in people with SARS‐CoV‐2: a systematic review and meta‐analysis
10.1002/edm2.176 · 2021 · External reference
Associations of BMI with COVID-19 vaccine uptake, vaccine effectiveness, and risk of severe COVID-19 outcomes after vaccination in England: a population-based cohort study
10.1016/s2213-8587(22)00158-9 · 2022 · External reference
Obesity or increased body mass index and the risk of severe outcomes in patients with COVID-19: A protocol for systematic review and meta-analysis
10.1097/md.0000000000028499 · 2022 · External reference
Unresolved reference
2017 · External reference
Efficacy and safety of three new oral antiviral treatment (molnupiravir, fluvoxamine and Paxlovid) for COVID-19: a meta-analysis
10.1080/07853890.2022.2034936 · 2022 · External reference
